This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fetterly, G. J.
Right arrow Articles by Nicolau, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fetterly, G. J.
Right arrow Articles by Nicolau, D. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2005, p. 148-152, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.148-152.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

Gerald J. Fetterly,1* Christine M. Ong,2 Sujata M. Bhavnani,1,{dagger} Jeffrey S. Loutit,3 Steven B. Porter,3 Lisa G. Morello,3 Paul G. Ambrose,1,{dagger} and David P. Nicolau2

Cognigen Corporation, Buffalo, New York,1 Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut,2 InterMune, Inc., Brisbane, California3

Received 25 February 2004/ Returned for modification 24 April 2004/ Accepted 25 September 2004

Oritavancin is a novel glycopeptide currently being developed for the treatment of complicated skin and skin structure infections (cSSSI), including those caused by multidrug resistant gram-positive pathogens. The disposition of oritavancin in skin structures was investigated using a cantharide-induced blister fluid model. Seventeen healthy male subjects received oritavancin, but only 16 subjects were evaluated after one subject discontinued study drug. Each subject (eight per dose group) received 200 mg of oritavancin once a day for 3 days (group A) or 800 mg as one single dose (group B). Group A plasma samples and exudates from blister fluid were collected on days 3, 4, 7, 9, and 12 and on days 3, 4, 7, and 9, respectively. Group B samples and exudates were collected on days 1, 2, 5, 7, and 10 and on days 1, 2, 5, and 7, respectively. Drug concentrations were determined using a liquid chromatography-tandem mass spectrometry assay and, subsequently, pharmacokinetic analysis was performed. Differences between treatment groups in ratios for area under the concentration-time curve for blister fluid and plasma (AUCblister fluid/AUCplasma ratios) were evaluated using a t test ({alpha} = 0.05). Mean maximum concentration of drug in plasma or blister fluid was approximately 8-fold and 11-fold higher in plasma than in blister fluid following the 200- or 800-mg doses of oritavancin, respectively. Mean AUCblister fluid/AUCplasma ratios at 24 h were 0.190 (standard deviation [SD], 0.052) and 0.182 (SD, 0.062) for groups A and B, respectively (P = 0.791). To place these results in a clinical context, mean drug concentrations in blister fluid exceed the oritavancin MIC at which 90% of strains are inhibited of Staphylococcus aureus (2 µg/ml) by approximately 2- to 5.5-fold at 12 h and 1.5- to 3-fold at 24 h following administration of both dosing regimens. These results support the potential use of oritavancin for the treatment of cSSSI.

* Corresponding author. Mailing address: Cognigen Corporation, 395 Youngs Rd., Buffalo, NY 14221-5831. Phone: (716) 633-3463, ext. 257. Fax: (716) 633-7404. E-mail: gerald.fetterly{at}cognigencorp.com.

{dagger} Present address: Institute of Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208.

Antimicrobial Agents and Chemotherapy, January 2005, p. 148-152, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.148-152.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rubino, C. M., Van Wart, S. A., Bhavnani, S. M., Ambrose, P. G., McCollam, J. S., Forrest, A. (2009). Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia. Antimicrob. Agents Chemother. 53: 4422-4428 [Abstract] [Full Text]  
  • McKay, G. A., Beaulieu, S., Sarmiento, I., Arhin, F. F., Parr, T. R. Jr., Moeck, G. (2009). Impact of Human Serum Albumin on Oritavancin In Vitro Activity against Enterococci. Antimicrob. Agents Chemother. 53: 2687-2689 [Abstract] [Full Text]  
  • McKay, G. A., Beaulieu, S., Arhin, F. F., Belley, A., Sarmiento, I., Parr, T. Jr, Moeck, G. (2009). Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 63: 1191-1199 [Abstract] [Full Text]  
  • Belley, A., Neesham-Grenon, E., McKay, G., Arhin, F. F., Harris, R., Beveridge, T., Parr, T. R. Jr., Moeck, G. (2009). Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro. Antimicrob. Agents Chemother. 53: 918-925 [Abstract] [Full Text]  
  • Heine, H. S., Bassett, J., Miller, L., Bassett, A., Ivins, B. E., Lehoux, D., Arhin, F. F., Parr, T. R. Jr., Moeck, G. (2008). Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax. Antimicrob. Agents Chemother. 52: 3350-3357 [Abstract] [Full Text]  
  • Nicolau, D. P., Sun, H. K., Seltzer, E., Buckwalter, M., Dowell, J. A. (2007). Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 60: 681-684 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»